GRAFAPEX Inflects While Medexus Doubles Down on Allo-HSCT

Q1 FY27 revenue +16% y/y, GRAFAPEX demand up 118% y/y; UM171 adds a second transplant-platform asset.

MDP.TO · Earnings Call · 2026-08-11

What Changed

Medexus entered fiscal 2027 with a quarter that felt less like a transition and more like an inflection. Net revenue rose to $28.6M from $24.6M a year earlier, adjusted EBITDA climbed to $4.7M (from $3.4M), and operating income more than doubled to $2.1M. The driver was unmistakable: launch of GRAFAPEX is now generating product-level net revenue of $4.9M in the quarter, with underlying patient demand of $4.8M — up 23% sequentially and 118% versus the same quarter last year. Management's confidence in the $30–32M full-year guidance rests on leading indicators, not hope.

So the reason we have confidence in the $30 million to $32 million is because of the leading indicators, which are obviously formulary listings, commercial support from the payers and then finally, first use from the hospitals.
Kenneth d'Entremont, Chief Executive Officer · 2026-08-11

That quote from CEO Ken d'Entremont captures the whole ballgame. Hospitals that tried the product are reordering; 54 of the 75 institutions that have ordered have placed repeat orders. And critically, the growth is now coming from the adult patients — the 85% of the market that matters most. As Ken noted on the call, “the growth we're experiencing is largely coming from the adult population... now this growth is happening from adult institutions and with adult patients.” “the growth that we're experiencing is largely coming from the adult population” — Kenneth d'Entremont, Chief Executive Officer · 2026-08-11 That mix shift is the real signal, because adult procedures use meaningfully more product than the pediatric cases that dominated early take-up.

UM171 and the Allo-HSCT Pivot

The quarter's most strategic event wasn't in the P&L — it was the signing of agreements for exclusive Canadian rights to UM171 cell therapy, a proprietary cell-source product that received conditional marketing authorization in Europe. The deal is textbook fit: UM171 is a cell source used after conditioning, exactly the stage where GRAFAPEX (treosulfan) is given. “The next step is to get in front of Health Canada and discuss the regulatory path forward” — Kenneth d'Entremont, Chief Executive Officer · 2026-08-11 The potential for an expedited approval (2028) versus a full clinical path (~2031) leaves optionality, but the strategic intent is clear — this is a company building a focused, transplant-centric rare disease portfolio, a deliberate break from its earlier broadly diversified specialty-pharma model. The keyword UM171 cell therapy did not appear in any of the prior five calls' keyword lists. It's new, company-defining, and it validates the platform thesis rather than a one-off licensing deal. Compare that to the more routine language around base products; the contrast is sharp.

The Base Business Is No Longer the Story

It's worth remembering how far the base has fallen — and how little that matters now. Rupall lost roughly two-thirds of its unit volume after genericization, and IXINITY remains durable but unexciting. The tariff on Rasuvo (15% on COGS) and potential tariff on GRAFAPEX are immaterial to margins. The one-time $1.3M royalty revenue from Gleolan in the comp year inflated prior margins, and stripping that out, gross margin actually improved despite the accounting noise. Net debt stands at $20.9M, up sequentially from $15.7M, but net-debt-to-EBITDA is a comfortable 1.18x. CFO Brendon Bushman was explicit about willingness to re-lever for the right deal: “historically, we had kind of gotten up into the 3x range... given the durability of our sort of established portfolio and our level of conviction on GRAFAPEX, we would be kind of comfortable getting back to that range” — Brendon Bushman, Chief Financial Officer · 2026-08-11 That's a meaningful structural shift: the balance sheet is now positioned to fund growth rather than just service debt.

What to Watch

The near-term cadence is favorable. Ken noted that July — historically a soft month — was the product's second-best month ever, and August/September tend to be stronger. Inventory at wholesalers has normalized to roughly one month, so the gap between demand and ex-factory revenue should stay tight, giving investors a cleaner read on the true growth trend. As Brendon put it: “we saw a strong... if you go back to the initial launch, wholesalers looking to hold 2-plus months... then over the course of the year, that kind of reduced to about 1x... that consistency continues” — Brendon Bushman, Chief Financial Officer · 2026-08-11 This is a micro-cap (~$127M market cap) that just proved its lead asset can grow 118% y/y in underlying demand while the rest of the portfolio holds up. The UM171 addition raises the ceiling, and the company is now willingly borrowing against that conviction. The risk is execution — Health Canada timeline, formulary conversion rate, and the eventual trajectory toward the $100–175M peak-sales range. But for a company that was written off as a generic-erosion story two years ago, the narrative has decisively turned.